| [1] |
Echt DS, Armstrong K, Schmidt P, et al. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator[J]. Circulation, 1985, 71(2): 289-296.
|
| [2] |
Mirowski M. The automatic implantable cardioverter-defibrillator: an overview[J]. J Am Coll Cardiol, 1985, 6(2): 461-466.
|
| [3] |
Healey JS, Hohnloser SH, Glikson M, et al. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)[J]. Lancet, 2015, 385(9970): 785-791.
|
| [4] |
Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications[J]. Heart Rhythm, 2016, 13(2): 443-454.
|
| [5] |
Providência R, Kramer DB, Pimenta D, et al. Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies[J]. J Am Heart Assoc, 2015, 4(11):e002418.
|
| [6] |
Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy[J]. N Engl J Med, 2020, 383(6): 526-536.
|
| [7] |
Boersma LV, El-Chami MF, Bongiorni MG, et al. Understanding outcomes with the EMBLEM S-ICD in primary prevention patients with low EF study (UNTOUCHED): Clinical characteristics and perioperative results[J]. Heart Rhythm, 2019, 16(11): 1636-1644.
|
| [8] |
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol. 2019, 74(7): e51-e156.
|
| [9] |
Kuschyk J, Stach K, Tülümen E, et al. Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices[J]. Heart Rhythm, 2015, 12(11):2230-2238.
|
| [10] |
de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice[J]. Heart, 2013, 99(14): 1018-1023.
|
| [11] |
Kutyifa V, Rosero SZ, McNitt S, et al. Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD[J]. Ann Noninvasive Electrocardiol, 2020, 25(4): e12744.
|
| [12] |
Kuschyk J, Falk P, Demming T, et al. Long-term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system[J]. Eur J Heart Fail, 2021, 23(7): 1160-1169.
|
| [13] |
Marzak H, Morel O, Jesel L. Inappropriate shock due to quadruple counting in a patient with subcutaneous implantable cardioverter-defibrillator and a dual-chamber pacemaker[J]. Europace, 2020, 22(5): 796.
|
| [14] |
Kossidas K, Kalman R, Follis WP, et al. Managing cross talk between a subcutaneous implantable cardioverter-defibrillator and a dual-chamber unipolar pacemaker system[J]. HeartRhythm Case Rep, 2017, 3(12): 579-583.
|
| [15] |
Huang J, Patton KK, Prutkin JM. Concomitant use of the subcutaneous implantable cardioverter defibrillator and a permanent pacemaker[J]. Pacing Clin Electrophysiol, 2016, 39(11): 1240-1245.
|
| [16] |
Ip JE, Wu MS, Kennel PJ, et al. Eligibility of pacemaker patients for subcutaneous implantable cardioverter defibrillators[J]. J Cardiovasc Electrophysiol, 2017, 28(5): 544-548.
|
| [17] |
Giammaria M, Lucciola MT, Amellone C, et al. Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators[J]. J Interv Card Electrophysiol, 2019, 54(1): 49-54.
|
| [18] |
Gauthey A, Calle S, Accinelli S, et al. His bundle pacing for newly acquired pacing needs in patients implanted with a subcutaneous implantable cardioverter defibrillator: A feasibility study based on the automated screening score and clinical cases[J]. J Cardiovasc Electrophysiol, 2020, 31(7): 1793-1800.
|
| [19] |
Perin F, Molina-Lerma M, Jiménez-Jáimez J, et al. Combined use of subcutaneous implantable defibrillator with endovenous left bundle branch pacing in a child with hypertrophic cardiomyopathy[J]. Rev Esp Cardiol (Engl Ed), 2021, 74(3):265-267.
|
| [20] |
Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-Year results from a pooled analysis of the IDE Study and EFFORTLESS registry[J]. J Am Coll Cardiol, 2015, 65(16): 1605-1615.
|
| [21] |
Mondésert B, Dubuc M, Khairy P, et al. Combination of a leadless pacemaker and subcutaneous defibrillator: First in-human report[J]. HeartRhythm Case Rep, 2015, 1(6):469-471.
|
| [22] |
Fernández-Palacios G, García-Morán E, Sandín-Fuentes M, et al. The utility of a combined synchronous atrioventricular leadless pacemaker and subcutaneous implantable cardiac defibrillator system in bilateral upper limb venous occlusion[J]. Europace, 2021, 23(5):814.
|
| [23] |
Breeman K, Swackhamer B, Brisben AJ, et al. Long-term performance of a novel communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study[J]. Heart Rhythm, 2022, 19(5):837-846.
|
| [24] |
van Opstal J, Geskes G, Debie L. A completely subcutaneous implantable cardioverter defibrillator system functioning simultaneously with an endocardial implantable cardioverter defibrillator programmed as pacemaker[J]. Europace, 2011, 13(1): 141-142.
|
| [25] |
Goto K, Ono Y, Osaka Y, et al. A sustained ventricular tachycardia overlooked by subcutaneous implantable cardioverter-defibrillator but recognized by co-implanted transvenous implantable cardioverter defibrillator[J]. HeartRhythm Case Rep, 2020, 6(6): 334-337.
|
| [26] |
Röger S, Borggrefe M, Kuschyk J. Heart failure with reduced ejection fraction and a narrow QRS complex: combination of a subcutaneous defibrillator with cardiac contractility modulation[J]. J Atr Fibrillation, 2015, 8(3):1081.
|
| [27] |
Kaczmarek K, Kałowski M, Wranicz JK, et al. Combined therapy with cardiac contractility modulation and subcutaneous implantable cardioverter-defibrillator: the first experience in Poland[J]. Kardiol Pol, 2018, 76(12):1740.
|
| [28] |
Trolese L, Faber T, Gressler A, et al. Device interaction between cardiac contractility modulation (CCM) and subcutaneous defibrillator (S-ICD)[J]. J Cardiovasc Electrophysiol, 2021, 32(11): 3095-3098.
|
| [29] |
Röger S, Rudic B, Akin I, et al. Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction[J]. Clin Cardiol, 2018, 41(4):518-524.
|
| [30] |
Black-Maier E, Lewis RK, Barnett AS, et al. Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: A case series and systematic review[J]. Heart Rhythm, 2020, 17(9): 1536-1544.
|
| [31] |
Ahmed AS, Patel PJ, Bagga S, et al. Troubleshooting electromagnetic interference in a patient with centrifugal flow left ventricular assist device and subcutaneous implantable cardioverter defibrillator[J]. J Cardiovasc Electrophysiol, 2018, 29(3): 477-481.
|